2'-amino-6',7'-dihydro-5'H-spiro[cyclopentane-1,8'-quinazolin]-4'-yl 4-methylbenzenesulfonate → N4'-{2-[(2-aminopyrimidin-4-yl)amino]ethyl}-6',7'-dihydro-5'H-spiro[cyclopentane-1,8'-quinazoline]-2',4'-diamine

Participants

Reaction Steps

The product from Example 10D (61 mg, 0.163 mmol) and the product from Example 1E (44 mg, 0.195 mmol) were treated under the conditions of Example 1F to afford the title compound. 1H NMR (300 MHz, DMSO-d6) δ ppm 1.41 (dd, J=11.19, 5.43 Hz, 2H) 1.47-1.57 (m, 2H) 1.57-1.69 (m, 4H) 1.69-1.83 (m, 2H) 1.96-2.09 (m, 2H) 2.16 (t, J=5.93 Hz, 2H) 3.33-3.52 (m, 4H) 5.45 (s, 2H) 5.66-5.77 (m, 1H) 5.84 (s, 2H) 6.20 (s, 1H) 6.89 (s, 1H) 7.61 (d, J=5.09 Hz, 1H); MS (ESI+) m/z 355.0 (M+H)+.

Provenance & Evidence